Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
During therapy with second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia, a number of patients demonstrate non-hematological toxicity of various degrees. The article contains review of references about second generation tyrosine kinase inhibitors effect on the frequ...
Main Author: | O. Y. Vinogradova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-10-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/154 |
Similar Items
-
Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu
Published: (2013-09-01) -
Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
by: Valeria Ciaffaglione, et al.
Published: (2022-05-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
Second-Line Therapy Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib
by: Chici Pratiwi, et al.
Published: (2022-12-01) -
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)